Reevaluating Antidepressant Selection in Patients With Bruxism and Temporomandibular Joint Disorder

Area of Science:

• Neurology
• Psychiatry
• Dental Medicine

Background:

• Temporomandibular joint disorder (TMD) is a complex pain condition affecting the jaw joint and masticatory muscles.
• TMD frequently co-occurs with depression and anxiety, necessitating pharmacological treatment.
• Selective serotonin reuptake inhibitors (SSRIs), a common antidepressant, can induce bruxism, potentially worsening TMD.

Purpose of the Study:

• To elucidate the mechanism of SSRI-induced bruxism.
• To review alternative antidepressant options for patients with TMD and bruxism.
• To identify antidepressants suitable for treating depression and anxiety in this patient population.

Main Methods:

• Literature review of studies on SSRI-induced bruxism.
• Analysis of alternative antidepressant classes: SNRIs, TCAs, atypical antidepressants, MAOIs.
• Evaluation of medications for managing SSRI-induced bruxism side effects.

Main Results:

• SSRIs may exacerbate TMD through induced bruxism.
• Dopamine agonists and buspirone show effectiveness in managing SSRI-induced bruxism side effects.
• Evidence for specific antidepressants that avoid bruxism in TMD patients remains inconclusive.

Conclusions:

• Careful consideration of antidepressant choice is crucial for TMD patients with comorbid depression/anxiety.
• Further research is needed to identify optimal antidepressant strategies that do not induce bruxism.
• Managing SSRI-induced bruxism is key to improving outcomes for TMD patients.